



INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

117-261

APPLICANT

BROWN

FILING DATE


January 11, 1999

SERIAL NO.

09/117,218

GROUP

5611



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

QW	°	Markert et al Neurosurgery, Vol. 32, No. 4, 4/93 pp 597-603 Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that retain Susceptibility to Acyclovir
I	°	Mineta et al Cancer Research 54, 3963-3966 1994 Treatment of Malignant Gliomas Using Gnciclovir-hypersensitive, Ribonucleotide Reductase-deficient Herpes Simplex Viral Mutant
I	°	Martuza et al Science Vol. 252, 854-856, 1991 Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
QW	°	Mineta et al Nature Medicine 1, 938-943, 1995 Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

*Examiner

Quang Nguyen

Date Considered

8 | 07 | 00

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)